Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q3 2025 Earnings Presentation
26 slides from Modus Therapeutics Holding Ab's earnings presentation, Nov 26, 2025
Slide 1: Modus Therapeutics Interim Report Q3 2025
MODUS THERAPEUTICS INTERIM REPORT Q3 2025 1
Slide 2: The Third Quarter in Brief
JANUARY 1 – SEPTEMBER 30, 2O25 THE THIRD QUARTER IN BRIEF The third quarter in figures • S evuparin doses selected for Part 2 of the • The loss after tax amounted to TSEK 4 342 (2 989). ongoing Phase IIa study in CKD anemia; protocol amendment submitted to regulatory authorities • The loss per share
Slide 3: Financial Overview
THE THIRD QUARTER IN BRIEF Important events after the end of the period Financial overview • On 24 Oct 2025, Modus appointed Bergs Securities AB as Certified Adviser; Bergs 2025 2024 2025 2024 2024 assumes the role on 27 Oct 2025, with Svensk Kapitalmarknadsgranskning AB (SKMG) The Group Jul 1 – Sep
Slide 4: Funding Secured, Advancing Clinical Trial in CKD
CEO STATEMENT FUNDING SECURED, ADVANCING CLINICAL TRIAL IN CKD WITH ANEMIA The third quarter was marked by strong execution on our clinical plans, successful financing, and expanding partnerships. Our team completed enrolment of Part 1 of the Phase IIa study of sevuparin in patients with CKD and ane
Slide 5: Our Operating Discipline and Improved Funding
CEO STATEMENT increasing Modus’ visibility with prospective severe malaria and sepsis. As we conclude Q3 partners and supporting future collaboration and 2025, we remain grateful to existing and new investment. Our interactions centered on Modus’ investors who participated in this quarter’s capital
Slide 6: About Modus Therapeutics
STATEMENT OF OPERATIONS ABOUT MODUS THERAPEUTICS Modus is developing sevuparin for patients with severe diseases and high unmet medical needs Modus Therapeutics is a Swedish biotechnology company developing sevuparin, an innovative drug candidate with the potential to transform the treatment of dise
Slide 7: Sevuparin – A Drug Candidate With Broad Clinical Potential
STATEMENT OF OPERATIONS SEVUPARIN – A DRUG CANDIDATE WITH BROAD CLINICAL POTENTIAL Modus Therapeutics is developing innovative for higher dosing without increased bleeding tecting the endothelium and neutralizing harmful stands out as an innovative drug candidate treatments for patients suffering fr
Slide 8: Market Overview
STATEMENT OF OPERATIONS MARKET OVERVIEW With sevuparin, Modus is targeting three The market potential is substantial. Modus, Anemia/CKD challenging indications—each with significant together with external analytics firm XPLICO, has standalone potential. identified an addressable market for sevuparin
Slide 9: Statement of Operations
STATEMENT OF OPERATIONS adapted mosquito vectors, and climate-related incentives in high-income countries. In the U.S., million deaths globally in 2017—about 20% of all changes that increase the incidence and severity malaria is classified as a rare disease (fewer global deaths that year. In the U.S
Slide 10: Business Model & Collaborations
STATEMENT OF OPERATIONS BUSINESS MODEL & COLLABORATIONS Business model operational and strategic capabilities. According to In non-endemic markets such as the US and EU, Given that sevuparin has the potential to be the first the current development plan, a market launch and malaria/severe malaria ma
Slide 11: Development of Profit and Financial Position
FINANCIAL REPORT DEVELOPMENT OF PROFIT AND FINANCIAL POSITION Third quarter Operating profit/loss The operating loss for July–September 2025 amounted to 4,226 (2,989) TSEK. Research and development expenses increased by 788 TSEK versus the same period last year, primarily driven by clinical activiti
Slide 12: Important Events During the Third Quarter
FINANCIAL REPORT Important events during the Extraordinary General Meeting held on 3. Issue authorisation 29 July 2025 The EGM authorised the Board—until the 2026 third quarter On 29 July 2025, Modus Therapeutics held AGM—to resolve, with or without pre-emptive Modus Therapeutics completed enrollmen
Slide 13: Financial Report
FINANCIAL REPORT Modus Therapeutics raises approximately SEK Upon full exercise of the warrants of series TO and the number of shares rose by 4,827,078 to sevuparin’s hepcidin-lowering mechanism and 28.3 million in oversubscribed unit issue 2026 and TO 2030, Modus could receive additional 121,628,49
Slide 14: Important Events After the End of the Period
FINANCIAL REPORT Important events after the end of the period Change of Certified Adviser to Bergs Securities AB On 24 October 2025, Modus announced that it had entered into an agreement with Bergs Securities AB to act as its Certified Adviser. Bergs Securities will assume the role on 27 October 202
Slide 15: Other Disclosures
FINANCIAL REPORT OTHER DISCLOSURES Ownership structure essary to pursue its operations and the strategic nary General Meeting on 29 July 2025—a directed and the CEO assess that these projects will be com- At the end of the third quarter 2025, there were 1 focus adopted by the Board. As Modus is prim
Slide 16: Consolidated Summary Income Statement
FINANCIAL REPORT Consolidated summary income statement 2025 2024 2025 2024 2024 TSEK Jul 1 – Sep 30 Jul 1 – Sep 30 Jan 1 – Sep 30 Jan 1 – Sep 30 Jan 1 – Dec 31 Net sales - - - - - Research and development costs -2 606 -1 818 -7 482 -6 214 -9 067 Administration costs -1 644 -1 149 -5 355 -4 749 -6 72
Slide 17: Consolidated Summary Balance Sheet
FINANCIAL REPORT Consolidated summary balance sheet 2025 2024 2024 TSEK Sep 30 Sep 30 Dec 31 Assets Fixed Assets Other financial fixed assets 52 51 52 Total fixed assets 52 51 52 Current assets Other receivables 872 560 453 Cash equivalents 16 534 7 999 4 379 Total current assets 17 406 8 559 4 832
Slide 18: Consolidated Change in Shareholders’ Equity
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2025 2024 2025 2024 2024 TSEK Jul 1 – Sep 30 Jul 1 – Sep 30 Jan 1 – Sep 30 Jan 1 – Sep 30 Jan 1 – Dec 31 Opening balance equity -6 744 9 838 2 137 17 681 17 681 Profit/loss for the period -4 342 -2 989 -13 223 -10 831 -15 545 To
Slide 19: Consolidated Cash Flow Statement
FINANCIAL REPORT Consolidated cash flow statement in summary 2025 2024 2025 2024 2024 TSEK Jul 1– Sep 30 Jul 1– Sep 30 Jan 1– Sep 30 Jan 1– Sep 30 Jan 1– Dec 30 Operating activities Operating profit/loss -4 225 -2 989 -12 813 -10 992 -15 838 Interest received - - - 160 292 Interest paid - - -1 - - C
Slide 20: Parent Company Income Statement
FINANCIAL REPORT Parent company income statement in summary 2025 2024 2025 2024 2024 TSEK Jul 1– Sep 30 Jul 1– Sep 30 Jan 1– Sep 30 Jan 1– Sep 30 Jan 1– Dec 31 Net sales 185 185 555 555 740 Research and development costs -385 -319 -1 126 -1 085 -1 450 Administration costs -1 473 -1 213 -4 917 -4 342
Slide 21: Parent Company Balance Sheet
FINANCIAL REPORT Parent company balance sheet 2025 2024 2024 2025 2024 2024 TSEK Sep 30 Sep 30 Dec 31 TSEK Sep 30 Sep 30 Dec 31 Assets Current liabilities Non-current assets Interest-bearing liabilities - - - Financial assets 70 052 70 051 70 052 Accounts payable 1 126 236 144 Total non-current asse
Slide 22: Notes
FINANCIAL REPORT NOTES Note 1. Accounting principles Note 4. Equity Modus Therapeutics Holding AB’s consolidated The share capital of the Parent Company accounts have been prepared in accordance consists only of fully paid ordinary shares with with the annual accounts act and the Swedish a nominal (
Slide 23: Signatures
FINANCIAL REPORT SIGNATURES The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also describes the principal risks and uncertainties faced by the parent
Slide 24: Quarterly Overview
FINANCIAL REPORT QUARTERLY OVERVIEW 2025 2024 2023 The Group Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Definitions Financial key ratio Net sales, TSEK - - - - - - - - - Operating profit Operating profit, TSEK -4 226 -5 873 -2 715 -4 846 -2 989 -4 804 -3 199 -3 771 -2 456 Operating income less operating expenses. E
Slide 25: Leadership Team & Board
LEADERSHIP TEAM & BOARD John Öhd, M.D., PhD Claes Lindblad Viktor Drvota, M.D, PhD Johan Dighed Ellen K. Donnelly, PhD CEO since 2020 and previously CMO since CFO since 2021. Chairman since 2016. Board Member since September 2024. Board Member since 2020. 2018. Born: 1967 Born: 1965 Born: 1973 Born:
Slide 26: Contact
Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden +46 (0)8-501 370 00 info@modustx.com www.modustx.com Contact John Öhd, CEO +46 (0)70-744 80 97 john.ohd@modustx.com Claes Lindblad, CFO & Head of IR +46 (0)70-246 75 54 claes.lindblad@modustx.com 26
Modus Therapeutics Holding — Q3 2025 Earnings Presentation on 6ix